Krsnaa Diagnostics Posts Strong FY26 Performance, Plans ₹500 Crore Capex

Krsnaa Diagnostics FY26 Net Profit ₹101.40 crore; Revenue ₹772.80 crore.

Reader Takeaway: Strong profit growth and operational efficiency improvements are positive, but government receivables and management turnover pose watch points.

What just happened

Krsnaa Diagnostics Limited announced its financial results for the fiscal year ending March 31, 2026 (FY '26). The company reported a consolidated revenue of ₹772.80 crore, marking a 7.77% increase from ₹717.10 crore in FY '25. Net profit (PAT) saw a significant jump of 30.67%, reaching ₹101.40 crore compared to ₹77.60 crore in the previous fiscal year. For the fourth quarter (Q4) of FY '26, revenue stood at ₹192.60 crore with a PAT of ₹41.70 crore, reflecting over 101% year-on-year growth in Q4 PAT.

Why this matters

The robust profit growth indicates improved profitability and operational effectiveness. The reduction in Days Sales Outstanding (DSO) from 155 days to 139 days in Q4 FY '26 demonstrates better working capital management, which is crucial for a Public-Private Partnership (PPP) model business. The planned ₹500 crore capital expenditure for FY '27 signals an aggressive growth strategy focused on expanding its Rajasthan project, MRI services, and retail infrastructure.

The backstory

Krsnaa Diagnostics operates primarily in the diagnostic services sector, often through PPP models with government hospitals. Historically, managing receivables from government entities has been a key operational challenge impacting cash flow. The company has been working on improving operational efficiencies and expanding its service offerings.

What changes now

With the announced capex, Krsnaa Diagnostics is set to significantly expand its footprint, particularly in Rajasthan. The retail segment, currently 8% of revenue, aims for 25-30% long-term. Improved DSO and a focus on operational efficiency are expected to bolster financial health. The recommended dividend of ₹2 per share offers a direct return to shareholders.

Risks to watch

Key concerns include potential delays in government receivables, as noted in HP and Karnataka projects. High-level management turnover, with recent resignations of CFO, CBO, and CEO, could also pose execution risks, although management assures stability. The conservative guidance for Rajasthan revenue, despite project potential, suggests a cautious ramp-up.

Peer comparison

While specific peer financial data for FY26 is not provided in the filing, Krsnaa Diagnostics' revenue growth of 7.77% and PAT growth of 30.67% should be assessed against industry averages. The company's focus on PPP models differentiates it from purely private diagnostic chains.

Context metrics (time-bound)

• FY '26 Revenue: ₹772.80 crore (up 7.77% YoY)
• FY '26 PAT: ₹101.40 crore (up 30.67% YoY)
• Q4 FY '26 PAT: ₹41.70 crore (up >101% YoY)
• DSO: Reduced from 155 days (Q3 FY '26) to 139 days (Q4 FY '26)
• Planned Capex (FY '27): ₹500 crore
• Dividend Recommended: ₹2 per share

What to track next

Investors will be keen to observe the execution of the ₹500 crore capex plan, the revenue ramp-up from Rajasthan and the retail segment, and the continued reduction in DSO and government receivables. Monitoring management stability will also be crucial.